Forte Biosciences (FBRX) Enterprise Value (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Enterprise Value data on file, last reported at -$58.2 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 26.92% year-over-year to -$58.2 million in Q1 2026; TTM through Mar 2026 was -$58.2 million, a 26.92% decrease from a year earlier, with the FY2025 full-year figure at -$77.0 million, down 31.85% from the prior year.
• Enterprise Value for Q1 2026 stood at -$58.2 million, up from -$77.0 million in the prior quarter.
• Over the last five years, Enterprise Value for FBRX reached as high as -$16.4 million in Q3 2024 and fell as low as -$106.1 million in Q2 2025.
• Historically, Enterprise Value has averaged -$48.4 million across 5 years, with a median of -$41.1 million in 2022.
• Across the five-year window, Enterprise Value surged 64.49% in 2024 and sank 469.51% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$41.1 million in 2022, then advanced by 9.67% to -$37.1 million in 2023, then plunged by 57.21% to -$58.4 million in 2024, then slumped by 31.85% to -$77.0 million in 2025, then grew by 24.37% to -$58.2 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$58.2 million in Q1 2026, -$77.0 million in Q4 2025, and -$93.4 million in Q3 2025.